Table 1 Clinical characteristics of the 71 patients evaluated, categorized by IPI scores

Age, years

0.592^†

  < 60

40

34

6

  ≥ 60

31

11

20

Follow-up duration

 Median years (range)

4.7 (0.7–21.8)

4.1 (1.0–21.8)

4.8 (0.7–14.6)

0.025^*

Laterality

0.614^†

 Right

42

29

13

 Left

23

12

11

 Bilateral

6

4

2

Nodal site involvement at diagnosis

0.348^†

 None

45

31

14

 Axillary ± supraclavicular

26

14

12

Presence of B-symptoms

NA

 Absent

71

45

26

 Present

0

0

0

Pathological classification

0.513^†

 DLBCL

57

35

22

 Others

14

10

4

Pathology

0.315^†

 Non-GCB

29

21

8

 GCB

23

14

9

 Unknown

5

Ann Arbor stage

0.342^†

 IE

39

27

12

 IIE

26

14

12

 IVE

6

4

2

Tumor Size in BUS1

0.047^†

  ≥ 5 cm

7

2

5

  < 5 cm

64

43

21

LDH

0.009^†

 Normal

34

29

5 11

 Elevated

26

12

14

 Unknown

11

4

7

β2-MG

0.541^†

 Normal

37

25

12

 Elevated

17

10

7

 Unknown

17

10

7

WBC

0.855^†

 Normal

61

37

24

 Elevated

3

2

1

 Unknown

7

6

1

Neut

0.622^†

 Normal

38

24

14

 Elevated

25

17

8

 Unknown

8

4

4

Lymph

0.894^†

 Normal

37

22

15

 Elevated

16

10

6

 Unknown

18

13

5

Ki-67 (%)

0.205^†

  < 50%

11

5

6

  ≥ 50%

57

37

20

 Unknown

3

3

0

BCL-2

0.333^†

 Positive

40

24

16

 Negative

25

17

8

 Unknown

6

4

2

BCL-6

0.535^†

 Positive

34

20

14

 Negative

10

7

3

 Unknown

27

18

9

c-Myc

0.990^†

 Positive

23

17

6

 Negative

26

15

11

 Unknown

22

13

9

Double-hit-lymphomas

0.333^†

 Yes

23

15

8

 No

26

17

9

 Unknown

22

13

9

Triple-hit-lymphomas

 Yes

16

8

8

0.217^†

 No

16

11

5

 Unknown

39

26

13

P53

0.556^†

 Positive

23

15

8

 Negative

23

12

11

 Unknown

25

18

7

CD30

0.936^†

 Positive

14

9

5

 Negative

27

17

10

 Unknown

30

19

11

CD5

0.910^†

 Positive

19

11

8

 Negative

32

19

13

 Unknown

20

15

5

EBER

0.094^†

 Positive

7

6

1

 Negative

51

33

18

 Unknown

13

6

7

Surgery

0.117^†

 Yes

44

30

14

 No

27

15

12

Circles of Chemotherapy

0.947^†

  < 4

2

1

1

  ≥ 4

51

32

19

 Unknown

18

12

6

Rituximab Given

0.033^†

 Yes

42

26

16

 No

13

4

9

 Unknown

16

15

1

RT

0.618^†

 Yes

9

7

2

 No

17

11

6

 Unknown

45

27

18

CNS prophylaxis administered

0.005^†

 Yes

6

3

3

 No or unknown

65

42

23